Additionally, we showed that the underlying mechanisms involve the development of hypoxic conditions in tumours and the activation of selected OATP genes that have not been previously reported as relevant for HCC development or treatment, such as OATP3A1. The gene discussed is SLCO1A2; the disease is hepatocellular carcinoma.